and get StockInvest.us Premium Subscription for FREE
Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
EXEL Price Targets and Analyst Ratings NASDAQ:EXEL
Historical Ratings and Targets
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-06-24 | 25.73% | BMO Capital | $28.00 | Initiates Coverage On | Outperform |
| 2022-02-18 | 88.59% | HC Wainwright & Co. | $52.00 $42.00 | Maintains | Buy |
| 2021-11-03 | 39.2% | RBC Capital | $32.00 $31.00 | Maintains | Outperform |
| 2021-11-03 | 133.5% | HC Wainwright & Co. | $65.00 $52.00 | Maintains | Buy |
| 2021-11-02 | 30.22% | Oppenheimer | $30.00 $29.00 | Maintains | Outperform |
| 2021-10-07 | 25.73% | Jefferies | $28.00 | Initiates Coverage On | Buy |
| 2021-09-20 | 61.65% | Truist Securities | $37.00 $36.00 | Maintains | Buy |
| 2021-06-28 | 34.71% | Needham | $33.00 $30.00 | Maintains | Buy |
| 2021-06-15 | 111.05% | HC Wainwright & Co. | $47.00 | Initiates Coverage On | Buy |
| 2021-04-19 | 16.75% | Morgan Stanley | $27.00 $26.00 | Maintains | Equal-Weight |
| 2021-03-31 | 34.71% | Credit Suisse | $30.00 | Initiates Coverage On | Outperform |
| 2021-03-12 | 57.16% | Wolfe Research | $35.00 | Initiates Coverage On | Outperform |
| 2021-02-16 | 61.65% | Piper Sandler | $33.00 $36.00 | Maintains | Overweight |
| 2020-12-16 | 21.24% | Morgan Stanley | $29.00 $27.00 | Maintains | Equal-Weight |
| 2020-10-26 | 21.24% | Stifel | $26.00 $27.00 | Maintains | Hold |
| 2020-09-22 | 30.22% | Morgan Stanley | $23.00 $29.00 | Maintains | Equal-Weight |
| 2020-09-21 | 66.14% | Oppenheimer | $33.00 $37.00 | Maintains | Outperform |
| 2020-09-21 | 48.18% | Piper Sandler | $30.00 $33.00 | Maintains | Overweight |
| 2020-08-07 | 3.28% | Morgan Stanley | $22.00 $23.00 | Maintains | Equal-Weight |
| 2020-07-15 | -1.21% | Morgan Stanley | $21.00 $22.00 | Maintains | Equal-Weight |
| 2020-06-01 | 43.69% | Oppenheimer | $28.00 $32.00 | Maintains | Outperform |
| 2020-05-14 | 79.61% | SunTrust Robinson Humphrey | $35.00 $40.00 | Maintains | Buy |
| 2020-05-06 | 21.24% | BMO Capital | $20.00 $27.00 | Maintains | Market Perform |
| 2020-05-06 | -5.7% | Morgan Stanley | $20.00 $21.00 | Maintains | Equal-Weight |
| 2020-04-21 | 25.73% | Oppenheimer | $25.00 $28.00 | Maintains | Outperform |
| 2020-04-20 | 48.18% | Needham | $28.00 $33.00 | Maintains | Buy |
| 2020-03-04 | 16.75% | Barclays | $26.00 | Initiates Coverage On | Overweight |
| 2020-02-26 | 3.28% | Stifel | $21.00 $23.00 | Maintains | Hold |
| 2020-02-26 | -10.19% | BMO Capital | $19.00 $20.00 | Maintains | Market Perform |
| 2020-01-13 | 39.2% | SunTrust Robinson Humphrey | $31.00 | Initiates Coverage On | Buy |
| 2020-01-13 | -5.7% | B of A Securities | $22.00 $21.00 | Reiterates | Buy |
| 2019-10-15 | 12.26% | Guggenheim | $33.00 $25.00 | Maintains | Buy |
| 2019-10-08 | -14.68% | BMO Capital | $23.00 $19.00 | Maintains | Market Perform |
| 2019-08-01 | 3.28% | Stifel | $22.00 $23.00 | Maintains | Hold |
EXEL Stock Trend
Given the current short-term trend, the stock is expected to fall -14.53% during the next 3 months and, with a 90% probability hold a price between $13.29 and $19.03 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-07-07 | $15.48 | $18.85 | $22.21 |
| 2022-07-08 | $15.42 | $18.78 | $22.14 |
| 2022-07-11 | $15.36 | $18.72 | $22.08 |
| 2022-07-12 | $15.29 | $18.66 | $22.02 |
| 2022-07-13 | $15.23 | $18.59 | $21.95 |
| 2022-07-14 | $15.17 | $18.53 | $21.89 |
| 2022-07-15 | $15.11 | $18.47 | $21.83 |
| 2022-07-18 | $15.04 | $18.40 | $21.77 |
| 2022-07-19 | $14.98 | $18.34 | $21.70 |
| 2022-07-20 | $14.92 | $18.28 | $21.64 |
| 2022-07-21 | $14.85 | $18.21 | $21.58 |
| 2022-07-22 | $14.79 | $18.15 | $21.51 |
| 2022-07-25 | $14.73 | $18.09 | $21.45 |
| 2022-07-26 | $14.66 | $18.03 | $21.39 |
| 2022-07-27 | $14.60 | $17.96 | $21.32 |
| 2022-07-28 | $14.54 | $17.90 | $21.26 |
| 2022-07-29 | $14.47 | $17.84 | $21.20 |
| 2022-08-01 | $14.41 | $17.77 | $21.13 |
| 2022-08-02 | $14.35 | $17.71 | $21.07 |
| 2022-08-03 | $14.28 | $17.65 | $21.01 |
| 2022-08-04 | $14.22 | $17.58 | $20.94 |
| 2022-08-05 | $14.16 | $17.52 | $20.88 |
| 2022-08-08 | $14.10 | $17.46 | $20.82 |
| 2022-08-09 | $14.03 | $17.39 | $20.76 |
| 2022-08-10 | $13.97 | $17.33 | $20.69 |
| 2022-08-11 | $13.91 | $17.27 | $20.63 |
| 2022-08-12 | $13.84 | $17.20 | $20.57 |
| 2022-08-15 | $13.78 | $17.14 | $20.50 |
| 2022-08-16 | $13.72 | $17.08 | $20.44 |
| 2022-08-17 | $13.65 | $17.02 | $20.38 |
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
